Key result
Pemafibrate was superior to omega-3 fatty acid ethyl in lowering fatty liver index and MASLD prevalence in patients with dyslipidemia receiving statin treatment.
Why the study?
Does pemafibrate improve fatty liver index and reduce MASLD prevalence compared to omega-3 fatty acid ethyl in patients with dyslipidemia on statin therapy?
RCT (n=117)
Does pemafibrate improve fatty liver index and reduce MASLD prevalence compared to omega-3 fatty acid ethyl in patients with dyslipidemia on statin therapy?
Pemafibrate may be more effective than omega-3 fatty acid ethyl in improving fatty liver index and reducing MASLD risk in statin-treated patients with dyslipidemia.
Background: Fatty liver index (FLI) calculated by using body mass index, waist circumference and levels of triglycerides and γ-glutamyl transpeptidase is a noninvasive biomarker for diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), which is one of the high-risk conditions of atherosclerotic cardiovascular diseases. To compare the effects of pemafibrate and omega-3 fatty acid ethyl on FLI, we conducted a sub-analysis study of the Pemafibrate Reduction of triglyceride-rich lipoproteins compared with Omega-3 fatty acid ethyl for Unmet needs in Dyslipidemic patients on target to apoB-48 (PROUD48) study. Methods: 57 participants in the pemafibrate 0.4 mg per day treatment group (PEMA, men/women: 37/20, mean 64 years) and 60 participants in the omega-3 fatty acid ethyl 4 g per day treatment group (OMEGA-3, men/women: 35/25, mean 63 years) in the PROUD48 study were included in the present study. Changes in FLI and prevalence of MASLD from baseline to week 16 in PEMA and OMEGA-3 were investigated. Results: = 0.582), respectively. Conclusions: Pemafibrate is superior to omega-3 fatty acid ethyl in lowering effects of FLI and MASLD in patients with dyslipidemia receiving statin treatment, suggesting that pemafibrate is a beneficial agent for hypertriglyceridemia and reduction of the risk for MASLD.
No takes yet. Share an insight, caveat, or question.
Takeda et al. (2025) conducted an RCT in Dyslipidemia treated with statin (n=117). Pemafibrate vs. Omega-3 fatty acid ethyl 4 g per day was evaluated on Changes in fatty liver index (FLI) and prevalence of MASLD from baseline to week 16 (p== 0.582). Pemafibrate was superior to omega-3 fatty acid ethyl in lowering fatty liver index and MASLD prevalence in patients with dyslipidemia receiving statin treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: